Maya L. Petersen MD, PhD

Associate Professor, Biostatistics & Epidemiology
Education: 
  • Fellow - Howard Hughes Medical Institute
  • MD - University of California, San Francisco
  • PhD - Biostatistics,  University of California, Berkeley
Research Interests: 
  • Causal inference
  • Dynamic treatment regimes
  • HIV
  • Antiretroviral resistance
Research Description: 

Dr. Petersen's research focuses on the development and application of novel causal inference methods to problems in health, with a focus on the treatment and prevention of HIV. She has a strong interest in and has published on the interface between biostatistics, epidemiology, and clinical medicine.

Selected Publications: 

Bembom O, Petersen ML, Rhee SY, Fessel WJ, Sinisi SE, Shafer R, van der Laan MJ. Biomarker discovery using targeted maximum likelihood estimation: Application to the treatment of antiretroviral resistant HIV infection.Statistics in Medicine : 2009 28(1):152-72.

Petersen ML , van der Laan MJ. Direct Effect Models. The International Journal of Biostatistics : 2008 4(1): Article 23.

Petersen ML, van der Laan MJ, Napravnik S, Eron J, Moore R, Deeks S. Long Term Consequences of the Delay between Virologic Failure of Highly Active Antiretroviral Therapy and Regimen Modification: a Prospective Cohort Study. AIDS : 2008 22(16):2097-106.

Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, and Bangsberg DR. Pillbox Organizers are Associated with Improved Adherence to HIV Antiretroviral Therapy and Viral Suppression: A Marginal Structural Model Analysis.Clinical Infectious Diseases : 2007 45(7):908-15.

Petersen ML, Deeks SG, van der Laan, MJ. Individualized Treatment Rules: Generating Candidate Clinical Trials.Statistics in Medicine: 2007 26(25):4578-601.

Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-Adjusted Marginal Structural Models to Estimate Time-Varying Effect Modification. American Journal of Epidemiology: 2007 166(9):985-93.

Petersen ML, van der Laan MJ, Response to Invited Commentary: Petersen et. al. Respond to "Effect Modification by Time-varying Covariates". American Journal of Epidemiology: 2007 166(9):1003-1004

Cordeiro SM, Neves AB, Ribeiro CT, Petersen ML, Gouveia EL, Ribeiro GS, Lobo TS, Reis JN, Salgado KM, Reis MG, Ko AI. Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil. Transaction of the Royal Society of Tropical Medicine and Hygiene. 2007 101(11):1147-53.

Petersen ML, Molinaro A, Sinisi SE, van der Laan MJ. Cross-validated Bagged Learning. Journal of Multivariate Analysis: 2007 98 (9): 1693-1704.

Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, WJ Fessel. Virologic Efficacy of Boosted Double vs. Boosted Single Protease Inhibitor Therapy AIDS: 2007 21(12): 1547-1554.

van der Laan MJ, Petersen ML. Statistical Learning of Origin-Specific Statically Optimal Individualized Treatment Rules. The International Journal of Biostatistics: 2007 3(1): Article 6

van der Laan MJ, Petersen ML. Causal Effect Models for Realistic Individualized Treatment and Intention-to-Treat Rules. The International Journal of Biostatistics: 2007 3 (1): Article 3

Sinisi SE, Polley EC, Petersen ML, Rhee SY, van der Laan MJ. Super Learning: an Application to Prediction of HIV-1 Drug Susceptibility. Statistical Applications in Genetics and Molecular Biology: 2007; 6(1): Article 7

Bembom O., Petersen ML, van der Laan MJ (2006). Identifying important explanatory variables for time-varying outcomes. In W. Dubitzky, M. Granzow, and D.P. Berrar (eds.), Fundamentals of Data Mining in Genomics and Proteomics, Springer, Chapter 11. pp. 227-250.

Petersen ML, Wang Y, van der Laan MJ, Bangsberg D. Assessing the Effectiveness of Antiretroviral Adherence Interventions: Using Marginal Structural Models to Replicate the Findings of Randomized Controlled Trials. JAIDS2006: 43 (Suppl 1): S96-S103

Petersen ML, Sinisi SE, van der Laan MJ. Estimation of direct causal effects. Epidemiology: 2006; 17(3): 276-284

Bastos FI, Malta M, Hacker M, Petersen ML, Sudbrack M, Colombo M, Caiaffa WT. (2006) Assessing Needle Exchange Operations in a Poor Brazilian Community. Substance Use and Misuse: 2006; 41(6-7): 937-51.

Petersen ML, Boily MC, Bastos FI. Assessing HIV resistance in developing countries: Brazil as a case study. Rev Panam Salud Publica: 2006; 19(3): 146-56.

van der Laan MJ, Petersen ML, Joffe MM. History-Adjusted Marginal Structural Models and Statically-Optimal Dynamic Treatment Regimens. The International Journal of Biostatistics: 2005; 1(1): 10-20 (Article 4). Read online

Malta, M, Petersen ML, Clair S, Freita F, Bastos FI. Adherence to antiretroviral therapy: a qualitative study with physicians from Rio de Janeiro, Brazil. Cadernos de Saúde Pública 2005; 21(5): 1424-1432.

Petersen ML, Travassos C, Bastos FI, Hacker MA, Beck EJ, de Noronha JC. The healthcare system and HIV epidemic in Brazil. In: Beck EJ, Mays N, Whiteside A, Zuniga JM, eds. The HIV Pandemic: local and global implications. 2005. Oxford: Oxford University Press.

Hacker MA, Petersen ML, Enriquez M, Bastos FI. Highly active antiretroviral therapy in Brazil: The challenge of universal access in a context of social inequality. Rev Panam Salud Publica. 2004; 16(2):78-83.

Bastos FI, Petersen ML, Kerrigan D, Boily MC. Management of HIV/AIDS: The Brazilian experience. In: Lévy JJ, Pierret J, Trottier G. Antiretroviral treatment: Experiences and challenges. 2004, Québec, Canada. Presses de l'Université du Québec. [French]

Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M, Slagado K, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. Journal of Infectious Diseases. 2003;187(1):109-16.

Steiner H, Petersen ML, Saxena K, Ford S, Matthews Z. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Journal of Clinical Psychiatry. 2003; 64(10):1183-91.

Profile Updated: April 7, 2016